 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
46 News |  |
- | Journal: Comparison table: Some drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
No abstract available
- || Review, Journal: Drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
No abstract available No abstract available
- |||| PF708 (teriparatide biosimilar) / China NT Pharma, Pfenex
FDA event: Alvogen and Pfenex’ PF708 (biosimilar, teriparatide) Receives FDA’s Approval for the Treatment of Osteoporosis @alvogenpr @Pfenex https://t.co/8CBAeOpklg (Twitter) - Oct 7, 2019
- ||||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Enrollment closed: A Comparison of PF708 and Forteo in Osteoporosis Patients (clinicaltrials.gov) - Aug 23, 2017
P3, N=168, Active, not recruiting, Sponsor: Pfenex, Inc
No abstract available Recruiting --> Active, not recruiting
- |||||||||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
New P3 trial: A Comparison of PF708 and Forteo in Osteoporosis Patients (clinicaltrials.gov) - Dec 22, 2016
P3, N=168, Recruiting, Sponsor: Pfenex, Inc
- ||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Trial completion: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - Aug 4, 2016
P1, N=70, Completed, Sponsor: Pfenex, Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Enrollment closed: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - May 4, 2016
P1, N=70, Active, not recruiting, Sponsor: Pfenex, Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
New P1 trial: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - Jan 15, 2016
P1, N=70, Recruiting, Sponsor: Pfenex, Inc